GlassScriptPhysician profile
Ellen H Kim
NPI 1912069329
$3,436.09
in general payments reported to CMS, 2019-2025
28 companies · $18.89 in 2025
The $18.89 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $474 · 2020: $447 · 2021: $1,159 · 2022: $686 · 2023: $475 · 2024: $176 · 2025: $18.89.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $670.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $670.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $697.45 | 2021-2025 | |
| Lilly USA, LLC | $466.76 | 2019-2023 | Jardiance, Mounjaro |
| Novo Nordisk INC | $380.68 | 2019-2023 | Ozempic |
| Bausch Health US, LLC | $298.99 | 2019-2023 | Aplenzin |
| Amgen INC. | $233.57 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $231.12 | 2019-2023 | Verquvo, Lagevrio, Belsomra |
| Kowa Pharmaceuticals America, INC. | $148.34 | 2019-2022 | |
| Amarin Pharma, INC. | $128.13 | 2020-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $122.18 | 2020-2022 | |
| Allergan, INC. | $80.42 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $78.75 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $68.59 | 2019-2022 | |
| Pfizer INC. | $58.53 | 2019-2023 | |
| Exact Sciences Corporation | $56.95 | 2023-2024 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $56.46 | 2021-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.63 | 2020-2021 | |
| Boston Scientific Corporation | $44.31 | 2024 | Wavewriter Alpha Prime 16 |
| Teva Pharmaceuticals USA, INC. | $30.79 | 2021 | |
| Novartis Pharmaceuticals Corporation | $30.48 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $28.98 | 2021 | |
| Dexcom, INC. | $24.25 | 2024 | Dexcom G6 Transmitter |
| Impel Pharmaceuticals INC. | $19.16 | 2023 | Trudhesa |
| Bayer Healthcare Pharmaceuticals INC. | $18.96 | 2022 | |
| Genentech USA, INC. | $18.34 | 2019 | |
| Astellas Pharma US INC | $18.32 | 2019 | |
| Vistapharm, INC. | $13.37 | 2021 | |
| Phadia US INC. | $13.31 | 2021 | |
| Endo Pharmaceuticals INC. | $13.27 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ellen Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.